Thomson Brian J
Department of Infectious Diseases, Nottingham University Hospitals, City Hospital Campus, Nottingham, UK.
Br Med Bull. 2009;89:153-67. doi: 10.1093/bmb/ldp003. Epub 2009 Jan 30.
Hepatitis C virus (HCV) is a major cause of liver disease worldwide. In industrialized countries, intravenous drug users (IDUs) are the main reservoir of infection. Relatively little information is available on HCV in the developing world.
Peer reviewed publications and presentations at major academic meetings.
HCV-related cirrhosis and death from hepatocellular carcinoma are likely to rise dramatically in the next three decades. Urgent intervention is required both to minimize the burden of disease in those already infected and to reduce the incidence of new infections, particularly in the IDU population.
Current models of care and commissioning in the UK and other countries do not adequately identify or treat HCV infection in IDUs. Most strategies focus on disease prevention and do not target new infections.
New models of care are currently being developed and validated.
The development of new models of HCV replication will transform our understanding and capacity to treat HCV infection.
丙型肝炎病毒（HCV）是全球肝病的主要病因。在工业化国家，静脉注射吸毒者（IDU）是主要的感染源。关于发展中世界的HCV信息相对较少。
同行评审出版物和在主要学术会议上的报告。
在未来三十年中，HCV相关的肝硬化和肝细胞癌导致的死亡可能会急剧上升。需要紧急干预，以尽量减少已感染者的疾病负担，并降低新感染的发生率，特别是在静脉注射吸毒者群体中。
英国和其他国家目前的护理和委托模式未能充分识别和治疗静脉注射吸毒者中的HCV感染。大多数策略侧重于疾病预防，并未针对新感染。
目前正在开发和验证新的护理模式。
HCV复制新模型的开发将改变我们对HCV感染的理解和治疗能力。
